Free Trial

Aurinia Pharmaceuticals (AUPH) Competitors

Aurinia Pharmaceuticals logo
$12.39 +0.39 (+3.22%)
As of 12:49 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AUPH vs. LEGN, ABVX, RNA, AXSM, NUVL, MRUS, CRSP, TGTX, CYTK, and ACAD

Should you be buying Aurinia Pharmaceuticals stock or one of its competitors? The main competitors of Aurinia Pharmaceuticals include Legend Biotech (LEGN), Abivax (ABVX), Avidity Biosciences (RNA), Axsome Therapeutics (AXSM), Nuvalent (NUVL), Merus (MRUS), CRISPR Therapeutics (CRSP), TG Therapeutics (TGTX), Cytokinetics (CYTK), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry.

Aurinia Pharmaceuticals vs. Its Competitors

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

Aurinia Pharmaceuticals has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500.

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are held by insiders. Comparatively, 0.0% of Legend Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Aurinia Pharmaceuticals has a net margin of 23.31% compared to Legend Biotech's net margin of -40.83%. Aurinia Pharmaceuticals' return on equity of 20.06% beat Legend Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Aurinia Pharmaceuticals23.31% 20.06% 13.81%
Legend Biotech -40.83%-32.00%-20.07%

Aurinia Pharmaceuticals has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurinia Pharmaceuticals$235.13M6.93$5.75M$0.4328.77
Legend Biotech$796.84M8.02-$177.03M-$0.88-39.36

In the previous week, Legend Biotech had 3 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 10 mentions for Legend Biotech and 7 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 1.67 beat Legend Biotech's score of 0.59 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aurinia Pharmaceuticals
7 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Legend Biotech
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Aurinia Pharmaceuticals currently has a consensus target price of $12.00, suggesting a potential downside of 3.01%. Legend Biotech has a consensus target price of $74.22, suggesting a potential upside of 114.26%. Given Legend Biotech's higher probable upside, analysts plainly believe Legend Biotech is more favorable than Aurinia Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurinia Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Legend Biotech
0 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.91

Summary

Aurinia Pharmaceuticals beats Legend Biotech on 10 of the 16 factors compared between the two stocks.

Get Aurinia Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AUPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AUPH vs. The Competition

MetricAurinia PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.63B$2.52B$5.76B$9.85B
Dividend YieldN/A48.51%6.66%4.49%
P/E Ratio28.7822.5182.4826.51
Price / Sales6.93524.31500.41161.56
Price / Cash38.8826.3325.7028.92
Price / Book4.856.7910.816.51
Net Income$5.75M$32.94M$3.28B$266.22M
7 Day Performance2.43%-0.46%-0.43%-1.21%
1 Month Performance8.06%5.01%6.47%3.32%
1 Year Performance77.26%-1.73%49.57%23.49%

Aurinia Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AUPH
Aurinia Pharmaceuticals
2.9852 of 5 stars
$12.37
+3.1%
$12.00
-3.0%
+79.6%$1.63B$235.13M28.78300News Coverage
Positive News
LEGN
Legend Biotech
3.5258 of 5 stars
$34.60
-2.7%
$73.00
+111.0%
-37.3%$6.36B$627.24M-39.322,609
ABVX
Abivax
3.2547 of 5 stars
$77.46
+0.2%
$92.33
+19.2%
+574.1%$5.85BN/A0.0061News Coverage
Positive News
Short Interest ↓
RNA
Avidity Biosciences
3.1991 of 5 stars
$45.27
-2.3%
$67.00
+48.0%
+16.1%$5.82B$10.90M-12.72190Positive News
AXSM
Axsome Therapeutics
4.7729 of 5 stars
$116.31
-1.9%
$178.00
+53.0%
+36.1%$5.80B$495.03M-22.94380News Coverage
Positive News
Analyst Forecast
Insider Trade
NUVL
Nuvalent
3.2422 of 5 stars
$74.05
-2.7%
$118.91
+60.6%
-4.9%$5.34BN/A-15.1140News Coverage
Positive News
Analyst Forecast
MRUS
Merus
3.0238 of 5 stars
$65.74
-2.6%
$88.64
+34.8%
+32.0%$4.97B$56.23M-11.9537News Coverage
Positive News
CRSP
CRISPR Therapeutics
3.5882 of 5 stars
$54.13
-0.3%
$71.60
+32.3%
+16.4%$4.92B$35M-9.97460Analyst Revision
TGTX
TG Therapeutics
4.3988 of 5 stars
$28.53
-3.1%
$46.25
+62.1%
+40.2%$4.53B$454.07M77.11290News Coverage
Positive News
CYTK
Cytokinetics
4.1774 of 5 stars
$37.01
-3.5%
$71.58
+93.4%
-8.4%$4.43B$18.47M-7.26250Trending News
Analyst Forecast
Insider Trade
Options Volume
ACAD
ACADIA Pharmaceuticals
4.0426 of 5 stars
$25.32
-1.6%
$28.88
+14.0%
+57.2%$4.27B$1.02B19.04510Analyst Revision

Related Companies and Tools


This page (NASDAQ:AUPH) was last updated on 9/4/2025 by MarketBeat.com Staff
From Our Partners